RT Journal Article
SR Electronic
T1 Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.13.23287200
DO 10.1101/2023.03.13.23287200
A1 Scholl, Jacqueline
A1 Panchal, Priyanka
A1 Nelissen, Natalie
A1 Atkinson, Lauren Z
A1 Kolling, Nils
A1 Saunders, Kate EA
A1 Geddes, John
A1 Rushworth, Matthew FS
A1 Nobre, Anna C
A1 Harrison, Paul J
A1 Harmer, Catherine J
YR 2024
UL http://medrxiv.org/content/early/2024/11/08/2023.03.13.23287200.abstract
AB Cognitive and neural mechanisms underlying bipolar disorder (BD) and its treatment are still poorly understood. Here we examined the role of adaptations in risk-taking using a reward- guided decision-making task.We recruited volunteers with high (n=40) scores on the Mood Disorder Questionnaire, MDQ, suspected of high risk for bipolar disorder and those with low-risk scores (n=37). We also recruited patients diagnosed with BD who were assigned (randomized, double-blind) to six weeks of lithium (n=19) or placebo (n=16) after a two-week baseline period (n=22 for FMRI). Participants completed mood ratings daily over 50 (MDQ study) or 42 (BD study) days, as well as a risky decision-making task and functional magnetic resonance imaging. The task measured adaptation of risk taking to past outcomes (increased risk aversion after a previous win vs. loss, ‘outcome history’).While the low MDQ group was risk averse after a win, this was less evident in the high MDQ group and least so in the patients with BD. During fMRI, ‘outcome history’ was linked to medial frontal pole activation at the time of the decision and this activation was reduced in the high risk MDQ vs. the low risk MDQ group. While lithium did not reverse the pattern of BD in the task, nor changed clinical symptoms of mania or depression, it changed reward processing in the dorsolateral prefrontal cortex.Participants’ modulation of risk-taking in response to reward outcomes was reduced as a function of risk for BD and diagnosed BD. These results provide a model for how reward may prime escalation of risk-related behaviours in bipolar disorder and how mood stabilising treatments may work.Key points Question: Do bipolar disorder and lithium treatment change adaptation of risk-taking over time?Findings: Across an observational study and a randomized controlled trial, we found that while participants modulate their risk taking in a gambling task over time, this was reduced as a function of risk for bipolar disorder. Neurally, this was accompanied by changes in reward memory traces in medial frontal pole.Meaning: The results show that bipolar disorder is linked to a reduction in adaptation of risk- taking to the environment, suggesting a possible computational mechanism and treatment target.Competing Interest StatementJS, PP, NN, LZA, NK, JG, MFSR report no biomedical financial interests or potential conflicts of interest. CJH has received consultancy payments from P1vital, Lundbeck, Compass Pathways, IESO, Zogenix (now UCB). PJH reports receiving an honorarium for editorial work for Biological Psychiatry and Biological Psychiatry Global Open Science. ACN is non-executive director at the Oxford Health Foundation Trust. KEAS has received consultancy payment from Yale University.Clinical TrialISRCTN91624955Funding StatementThe study was funded by a Wellcome Trust Strategic Award (CONBRIO: Collaborative Oxford Network for Bipolar Research to Improve Outcomes, reference No. 102,616/Z). JRG, CJH, PJH and KEAS are supported by the Oxford Health NIHR Biomedical Research Centre. MFSR is funded by the Wellcome Trust (221794/Z/20/Z). The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z). JS has been funded by the Institut National de la Sante et de la Recherche Medicale, the Biotechnology and Biological Sciences Research Council (BB/V004999/1, Discovery Fellowship) and Medical Research Council (MR/N014448/1, Skills Development Fellowship). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Oxford University Ethics Committee gave ethical approval for this work (MSD-IDREC-C2-2014-023). The South Central - Oxford A Research Ethics Committee gave ethical approval for this work (15/SC/0109).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.